KalVista Pharmaceuticals Inc (KALV) Q3 2026 Earnings Call Highlights: Strong EKTERLY Launch and ... [Yahoo! Finance]
KalVista Pharmaceuticals, Inc. (KALV)
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kalvista.com
Company Research
Source: Yahoo! Finance
Operating Expenses: Total operating expenses were $59.7 million, with $12 million in R&D expenses and $46.5 million in SG&A expenses. Cash Position: Sufficient to fund operations through profitability due to recent convertible note financing. Gross to Net: Came in toward the low end of the expected range, driven by lower copay utilization. Warning! GuruFocus has detected 5 Warning Signs with KALV. Is KALV fairly valued? Test your thesis with our free DCF calculator. Release Date: November 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points EKTERLY's launch in the US has shown strong demand and adoption, with significant usage in treating HAE attacks. The German launch of EKTERLY has validated international interest, with approvals expanding to Australia, UK, EU, and Switzerland. The KONFIDENT-KID trial for children with HAE has been fully recruited ahead of schedule, highlighting unmet needs
Show less
Read more
Impact Snapshot
Event Time:
KALV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KALV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KALV alerts
High impacting KalVista Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KALV
News
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results [Yahoo! Finance]Yahoo! Finance
- KalVista Pharmaceuticals (NASDAQ:KALV) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at HC Wainwright from $27.00 to $37.00. They now have a "buy" rating on the stock.MarketBeat
- KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results [Yahoo! Finance]Yahoo! Finance
KALV
Earnings
- 11/10/25 - Beat
KALV
Sec Filings
- 1/26/26 - Form S-8
- 1/21/26 - Form 4
- 1/21/26 - Form 4
- KALV's page on the SEC website